Physiological changes at altitude in nonasthmatic and asthmatic subjects

Dianna Louie1,2, Peter D Paré MD FRCPC2


Exercised-induced asthma is not due to exercise itself per se, but rather is due to cooling and/or drying of the airway because of the increased ventilation that accompanies exercise. Travel to high altitudes is accompanied by increased ventilation of cool, often dry, air, irrespective of the level of exertion, and by itself, this could represent an 'exercise' challenge for asthmatic subjects. Exercise-induced bronchoconstriction was measured at sea level and at various altitudes during a two-week trek through the Himalayas in a group of nonasthmatic and asthmatic subjects. The results of this study showed that in mild asthmatics, there was a significant reduction in peak expiratory flow at very high altitudes. Contrary to the authors' hypothesis, there was not a significant additional decrease in peak expiratory flow after exercise in the asthmatic subjects at high altitude. However, there was a significant fall in arterial oxygen saturation postexercise in the asthmatic subjects, a change that was not seen in the nonasthmatic subjects. These data suggest that asthmatic subjects develop bronchoconstriction when they go to very high altitudes, possibly via the same mechanism that causes exercise-induced asthma.

Key Words: Altitude; Asthma; Bronchoconstriction; Exercise

PATIENTS AND METHODS

The subjects in this study were 10 nonasthmatics and five asthmatics. The subjects were all residents of the lower mainland of British Columbia. The anthropometric and baseline physiological data for these individuals are shown in Table 1. The diagnosis of asthma was based on doctor's diagnosis. All of the asthmatics had relatively mild, controlled asthma; all had used an antiasthma medication at some time, but at the time of baseline measurements, only one was receiving regular therapy, consisting of inhaled salbutamol before exercise. During the trek, this individual also added 400 mg of budesonide (Pulmicort, AstraZeneca, Canada) twice per day; the other asthmatics subjects used, as needed, inhaled bronchodilators without inhaled or oral corticosteroids. For one day at the highest altitude on the trek, all of the individuals, including the nonasthmatic subjects, received either dexamethasone 4 mg or diamox 250 mg.

At sea level, before the trek and on the return, all of the subjects had measurements taken of peak expiratory flow (PEF) rate, blood pressure, heart rate and oxygen saturation. These
measurements were taken before and immediately after a 200 m run. Measurements of PEF rate were always performed in the morning at approximately the same time of day. The oxygen saturation was measured using an oxygen saturation monitor (Nonin 8500M, Medical Inc, USA), PEF was measured using a peak flow meter (Breath-Alert, Carestream Medical, Australia and New Zealand), and blood pressure was measured using a blood pressure cuff (Tycos, Certified 6605315, USA) and stethoscope (Hewlett-Packard, USA).

RESULTS

Figure 1 shows the various locations at which measurements were taken before and immediately after a 200 m run. Measurements of PEF rate were always performed in the morning at approximately the same time of day. The oxygen saturation was measured using an oxygen saturation monitor (Nonin 8500M, Medical Inc, USA), PEF was measured using a peak flow meter (Breath-Alert, Carestream Medical, Australia and New Zealand), and blood pressure was measured using a blood pressure cuff (Tycos, Certified 6605315, USA) and stethoscope (Hewlett-Packard, USA).

Figure 1) Altitude at different locations at which physiological measurements were taken, beginning in Vancouver, and reaching the highest elevations of 3500 m and 4100 m at Manang and Churi Latter, respectively. The vertical axis on the right shows the average pre-exercise oxygen saturation measurements (mean ± SD) for all subjects, illustrating the expected decrease in resting oxygen saturation and the return to baseline values on return to Vancouver.

Figure 2) Mean values for peak expiratory flow (PEF) (L/min) at different locations and altitudes for nonasthmatic and asthmatic subjects. There was no change in mean PEF rates for the nonasthmatic subjects at any location. However, the PEF rates at Manang and Churi Latter were significantly reduced relative to values taken at sea level in the asthmatic subjects. The flow rates appear to decrease steeply between 2600 m and 3500 m in the asthmatic subjects with P<0.05. At the highest altitude, mean resting rates for the asthmatic and nonasthmatic subjects were 92±4 beats/min and 85±6 beats/min, and peak postexercise heart rates were 128±7 beats/min and 133±9 beats for these groups, respectively (P>0.05).

At sea level pre-exercise, the per cent predicted PEF rates for the nonasthmatic and asthmatic subjects were 101±9.3 L/min and 107.8±21.5 L/min, respectively. Figure 2 shows the PEF values at the different locations and elevations pre-exercise in asthmatics and nonasthmatic subjects. At baseline, the asthmatic subjects had a slightly higher average PEF than nonasthmatic subjects; however, when this was expressed as per cent predicted, there was no significant difference between the groups. What is apparent is that there was a significant decrease in PEF with increasing altitude in the asthmatic but not in the nonasthmatic subjects. When PEF values at the two highest elevations were compared with the mean PEF values at sea level, there was a significant decrease in PEF in the asthmatic subjects (–76±67 L/min, P<0.05) but a nonsignificant decrease in the nonasthmatic subjects (–14±23 L/min, P>0.05).

Figure 3 shows the changes in PEF from pre- to postexercise in the nonasthmatic and asthmatic subjects at the highest altitude reached. For this analysis, values for pre- and postexercise PEF at 3500 m and 4100 m were combined. There was no significant additional decrease in PEF flow after exercise in either the nonasthmatic or asthmatic subjects.

Figure 4 shows mean values for oxygen saturation pre- and postexercise in the nonasthmatic and asthmatic subjects at the two highest altitudes reached. There was a small but not significant decrease in oxygen saturation in the nonasthmatic subjects, but there was a significant further decrease in oxygen saturation in the asthmatics postexercise (P<0.04).

TABLE 1

<table>
<thead>
<tr>
<th>Anthropometric and baseline physiological data for nonasthmatic and asthmatic subjects in a study examining physiological changes at altitude</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of subjects</td>
</tr>
<tr>
<td>Male/female (n)</td>
</tr>
<tr>
<td>Age (years) (mean ± SD)</td>
</tr>
<tr>
<td>Height (cm) (mean ± SD)</td>
</tr>
<tr>
<td>Weight (kg) (mean ± SD)</td>
</tr>
<tr>
<td>Peak expiratory flow (L/min) (mean ± SD)</td>
</tr>
<tr>
<td>Mean arterial pressure (mmHg) (mean ± SD)</td>
</tr>
<tr>
<td>Heart rate (beats/min) (mean ± SD)</td>
</tr>
<tr>
<td>Oxygen saturation (%) (mean ± SD)</td>
</tr>
</tbody>
</table>
Can Respir J Vol 11 No 3 April 2004

**DISCUSSION**

The results of this study shows that in mild asthmatic subjects, there was a significant reduction in PEF at high altitudes in the Himalayas. Contrary to our hypothesis, there was not a significant additional decrease in PEF after exercise in the asthmatic subjects at altitude. However, there was a significant fall in arterial oxygen saturation postexercise in the asthmatic subjects, a change that was not seen in the nonasthmatic subjects. These data suggest that mild asthmatic subjects develop bronchoconstriction at very high altitudes. Bronchoconstriction pre-exercise in these subjects may be related to the same mechanism that causes exercise-induced asthma. High altitude exposure is associated with excessive ventilation because of hypoxic conditions; in addition, the air temperature at the two highest locations was substantially lower than body temperature (Manang 8°C, Churi Latter 0°C), and the water content of air at these temperatures is substantially lower than the 47 mg/L that is present in fully saturated air at body temperature (3). Thus, simply going to a high altitude constitutes an ‘exercise’ challenge to asthmatic subjects. Interestingly, the asthmatics did not develop further bronchoconstriction during exercise at high altitudes, perhaps because their ventilation increased little beyond the marked hyperpnea already present. Although the subjects all attempted to run the prescribed 200 m at high altitude, they did so very slowly. Also, though measurements of ventilation during exercise were not obtained, it is possible that the increase in ventilation due to being at high altitude was as great or greater than that caused by exercise.

Despite this, the asthmatic subjects developed a significant fall in arterial oxygen saturation postexercise, a change that was not seen in the nonasthmatic subjects. There is evidence that arterial oxygen saturation is extremely dependent on the maintenance of alveolar ventilation at high altitudes (4). This is because diffusion becomes critically important for arterial oxygen saturation at altitude, and it is likely that a true alveolar capillary gradient for oxygen occurs when there are these extremely low values of alveolar oxygen. The fall in oxygen saturation among the asthmatic subjects appears to be out of proportion to the decrease in inspiratory flow. It may be that at low inspired oxygen pressures, small increases in ventilation-perfusion rates mismatch have more effect on gas exchange at altitude than they would at sea level.

These data suggest that people with asthma are more prone to develop high altitude hypoxemia, predominantly related to bronchoconstriction occurring because of increased ventilation and cold, dry air conditions at altitude. The subjects in this study all had mild, well-controlled cases of asthma, and the results may not be generalizable for a broad range of asthmatic subjects. The asthmatic subjects were not specifically treated for exercise-induced bronchoconstriction, and it is possible that regular therapy with inhaled corticosteroids and/or regular beta-adrenergic agonists may have attenuated or blocked this high altitude bronchoconstriction. However, the study was not designed to test this hypothesis. Although when properly controlled, people with asthma can lead a normal lifestyle, including going to high altitudes, these results suggest that they may develop mild bronchoconstriction and hypoxemia at high altitudes.

**ACKNOWLEDGEMENTS:** Ms Louie acknowledges the support of Mr Brian Sheffield, Dr Geoff Gabbutt, Steve Brewster, Mr Ken Louie and Dr Heather Louie. Ms Louie’s expedition to Nepal was sponsored in part by AstraZeneca, GlaxoSmithKline, Nesbitt Burns, Mead Johnson and the British Columbia Lung Association.

**REFERENCES**

Submit your manuscripts at http://www.hindawi.com